

REMARKS

Claims 1, 2, 10, 12-15, 21, 25, 27, 28, 31, 47, 48, 56, 57, 77-81, 84, 88, 98, and 101 are pending in the application and are currently allowed. Claims 81 and 88 have been amended. Accordingly, claims 1, 2, 10, 12-15, 21, 25, 27, 28, 31, 47, 48, 56, 57, 77-81, 84, 88, 98, and 101 will remain pending in the application.

Claims 81 and 88 have been amended to correct typographical errors and to make minor editorial changes. Support for the claim amendments can be found throughout the specification as filed and original claims. In particular, support for the amendments is at least found in the originally filed specification at page 22, lines 17-22. No new matter has been added.

In an interview on December 2, 2010, Examiner and Applicants' representative discussed an Examiner's Amendment to place the claims in condition for allowance. Among the issues discussed in the interview was the enablement of claims 81 and 88, which provide methods of treatment of inflammation disorders or diseases. In particular, Examiner and Applicants' representative discussed the inflammation disorders and diseases recited in claims 81 and 88, and the Examiner's position on the enablement of the methods of treatment regarding the recited inflammation disorders and diseases.

It is Applicants' recollection that the Examiner considered methods of treatment were enabled for inflammatory disorders or diseases clearly linked with inflammation (e.g., acute inflammatory disease, sepsis, septic shock, rheumatoid arthritis, meningitis, inflammatory bowel diseases, Crohn's disease, chronic obstructive pulmonary disease, and rhinitis), but not enabled for the full scope of diseases or conditions of severe shock, cancer, cancer metastasis, infectious disease, and preterm labor. Applicants were agreeable to an amendment of claims 81 and 88 to recite inflammatory disorders or diseases clearly linked with inflammation to place the claims in condition for allowance. At the time, it was Applicants understanding that claims 81 and 88 reciting an inflammatory

bowel disease would be allowed, as inflammatory bowel diseases are clearly linked with inflammation.

On March 7, 2011, Applicants discussed the omission of inflammatory bowel disease from the inflammation disorders and diseases recited in claims 81 and 88 of the Examiner's Amendment. However, the Examiner could not recall a reason for the omission of inflammatory bowel disease from claims 81 and 88. Thus, Applicants believe the omission of inflammatory bowel disease to be a clerical or typographical error on the Notice of Allowance.

As no new matter has been added and no new issues would be raised by entry of the amendment to claims 81 and 88, entry of this Amendment After Allowance is proper pursuant to 37 CFR 1.312, and such action is respectfully requested.

CONCLUSION

Applicants believe that all the claims presented herein are in condition for allowance and respectfully request early and favorable consideration and entry of the claims presented herein. If the Examiner considers that obstacles to allowance persist, Applicants invite the Examiner to call the undersigned at the telephone number listed below to resolve any remaining obstacles.

In the event that an extension of time is required and has been overlooked, Applicants conditionally petition for any necessary extension. The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 04-1105, under Attorney Docket No. 61959(51580), Customer No. 21874.

Dated: March 9, 2011

Respectfully submitted,

Electronic signature: /Elbert Chiang, Ph.D./
Elbert Chiang, Ph.D.
Registration No.: 60,325
EDWARDS ANGELL PALMER & DODGE
LLP
P.O. Box 55874
Boston, Massachusetts 02205
(617) 517-5502
Attorneys/Agents For Applicant